Instruments

Name Stock exchange Average volume Price Type
PERELLA WEINBERG PARTNERS PWP

Nasdaq

387,047 15.32 USD Stock Perella Weinberg Partners Stock
FAKTOR-OPTIONSSCHEIN - VONT 6X S URI

Börse Stuttgart

- 0.076 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 6X S URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 3X L URI

Börse Stuttgart

- 24.77 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 3X L URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 4X S URI

Boerse Frankfurt Warrants

- 0.86 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 4X S URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 5X L URI

Boerse Frankfurt Warrants

- 32.03 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 5X L URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 3X L URI

Boerse Frankfurt Warrants

- 25.55 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 3X L URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 6X L URI

Boerse Frankfurt Warrants

- 32.1 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 6X L URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 2X S URI

Deutsche Boerse AG

- 3.7 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 2X S URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 5X S URI

Deutsche Boerse AG

- 0.33 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 5X S URI Certificat
FAKTOR-OPTIONSSCHEIN - VONT 4X S URI

Deutsche Boerse AG

- 0.86 EUR Certificat FAKTOR-OPTIONSSCHEIN - VONT 4X S URI Certificat

News (48)

Ceragon : NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K PU
Transcript : NovoCure Limited - Special Call
Transcript : NovoCure Limited, Q3 2023 Earnings Call, Oct 26, 2023
Novocure Announces Organizational Changes to Prepare for Future Growth BU
Elon R. Musk completed the acquisition of remaining 90.4% stake in Twitter, Inc. from Al waleed bin Talal, Kingdom Holding Company, The Vanguard Group, Inc. and others. CI
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology BU
Transcript : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program BU
Elon R. Musk made a non-binding proposal to acquire remaining 90.4% stake in Twitter, Inc. from Al waleed bin Talal, Kingdom Holding Company, The Vanguard Group, Inc. and others for $41.4 billion. CI
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields BU
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial BU
Transcript : NovoCure Limited, Q4 2021 Earnings Call, Feb 24, 2022
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response BU
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program BU
Exor N : Half-Year 2021 Financial Report PU
Transcript : NovoCure Limited, Q2 2021 Earnings Call, Jul 29, 2021
Novocure : Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer BU
Transcript : NovoCure Limited, Q1 2021 Earnings Call, Apr 29, 2021
Novocure : Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields BU
Transcript : NovoCure Limited, Q4 2020 Earnings Call, Feb 25, 2021
Transcript : NovoCure Limited Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-12-2021 05:20 AM
Transcript : NovoCure Limited Presents at Evercore ISI 3rd Annual HealthCONx Conference, Dec-02-2020 11:20 AM
Novocure : to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference BU
Transcript : NovoCure Limited - Shareholder/Analyst Call
Novocure : Announces Agenda for Virtual Research and Development Day BU
Transcript : NovoCure Limited, Q3 2020 Earnings Call, Oct 29, 2020
Transcript : NovoCure Limited Presents at Wells Fargo Securities 2020 Virtual Healthcare Conference, Sep-09-2020 08:40 AM
Novocure : to Participate in the 2020 Wells Fargo Virtual Healthcare Conference BU
Novocure : and the AACR Announce 2nd Annual AACR-Novocure : Grants for Tumor Treating Fields Research Program BU
Novocure : Announces 10 Oral Presentations and a Special Session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biology Conference BU
Novocure : Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019 BU
Novocure :’s Chief Science Officer Retires after 17 Years of Service BU
Novocure Announces Executive Changes CI
Brookfield Asset Management Inc. (TSX:BAM.A) completed the acquisition of Forest City Realty Trust, Inc. (NYSE:FCE.A) from Starboard Value LP, Scopia Capital Management LP, RMS Limited Partnership and others. CI
Brookfield Asset Management Inc. (TSX:BAM.A) entered into a definitive agreement to acquire Forest City Realty Trust, Inc. (NYSE:FCE.A) from Starboard Value LP, Scopia Capital Management LP, RMS Limited Partnership and others for $6.9 billion. CI
Novocure : Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society BU
Novocure : to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer BU
NovoCure Limited to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer CI
Novocure : Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma PU
Novocure : Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma BU
Cannabics Pharmaceuticals Inc. Announces Executive Changes CI
Novocure : Announces Agenda for Research and Development Day on Dec. 12, 2016 BU
Novocure : Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer BU
Novocure : to Present Clinical Trial Designs and Preclinical Data on Tumor Treating Fields at the 16th World Conference on Lung Cancer BU
Novocure : Launches Clinical Trial Website at www.novocuretrials.com BU
12NextSee all

Companies (3)

NHPC LIMITED 11 147 M $
Logo NHPC Limited

NHPC Limited is an India-based company that is primarily involved in the generation and sale of bulk power to various power utilities. The Company’s other business activities include project management / construction contracts/ consultancy assignment se ...

BVZ HOLDING AG 220 M $
Logo BVZ Holding AG

BVZ Holding AG is a Switzerland-based holding company primarily engaged in the operation of railways in the cantons Wallis, Uri and Graubuenden in Switzerland. The Company has two wholly owned subsidiaries: BVZ Asset Management AG, which provides real est ...

GULLIVER ENERGY LTD - $
Logo Gulliver Energy Ltd

Gulliver Energy Ltd, formerly Simcha Urieli & Sons Engineering & Construction Co. Ltd., is an Israel-based company that is engaged in the oil and gas exploration sector. ...


Insiders

Picture Uri Weinberg
Uri Weinberg

Currently, Uri Weinberg is Chief Science Officer at NovoCure Ltd. Dr. Weinberg received a doctorate from Israel Institute of Technology.




Picture Peter Weinberg
Peter Weinberg

Peter Amory Weinberg is the founder of Perella Weinberg Partners Capital Management LP, where he holds the title of Founding Partner & Chairman since 2007.
He was also the founder of Perella Weinberg Partners LP, where he held the title of Founding Partner & Chief Executive Officer from 2005 to 2023.
Mr. Weinberg is currently the Chief Executive Officer of PWP Holdings LP and the Chairman of Perella Weinberg Partners.
He also holds positions as a Director at Claremont McKenna College, Memorial Sloan-Kettering Cancer Center (Investment Management), and Memorial Sloan Kettering Cancer Center, where he serves as Secretary & Trustee.
Mr. Weinberg's former positions include Chief Executive Officer at Goldman Sachs International from 1988 to 2006, Chairman of Business-Higher Education Forum, Director at GLG Partners, Inc., Director at Fintech Acquisition Corp.
VI, Trustee at Deerfield Academy, Trustee at Harvard Business School, Founding Trustee at King's Academy, Trustee at Brunswick School, Inc., and Trustee at The Henry Kravis Leadership Institute.
Mr. Weinberg received his undergraduate degree from Claremont McKenna College and his MBA from Harvard Business School.
Mr. Weinberg is also the founder of Financial Sponsors Group, Weinberg Family Cerebral Palsy Center.





Picture Eliezer Weinberg
Eliezer Weinberg

Mr. Eliezer Weinberg is Chairman at Villar International Ltd.
He is on the Board of Directors at Green Biofuels Corp., Wapis Business Development Ltd., Green Biofuels Holding Ltd., and Liraz Batteries Ltd.
Mr. Weinberg was previously employed as Non-Executive Chairman by Blue Sphere Corp.
He received his undergraduate degree from The Hebrew University of Jerusalem and a graduate degree from the Technion-Israel Institute of Technology.



Picture Jim Weinberg
Jim Weinberg

Jim Weinberg is currently working as Vice President-Asset Acceptance at PENSCO Trust Co. since 2007.
Prior to this, he worked as a Specialist-IRA Brokerage Operations at Bank of America Corp.
from 1992 to 1999.
He also served as Chief Operations Officer at WESCO International, Inc. and Nationwide Funding Corp.
from 1982 to 1989.
Mr. Weinberg completed his undergraduate degree from San Francisco State University.

No results for this search